公开(公告)号：US20180148437A1

公开(公告)日：2018-05-31

申请号：US15383413

申请日：2016-12-19

Applicant: Georgetown University

Inventor： Milton L. Brown ,  Mikell Paige ,  Jeffrey A. Torestsky ,  Aykut Uren ,  George Kosturko ,  Gullay Bulut

IPC: C07D413/12 ,  C07D401/12 ,  C07D215/24 ,  C07D471/04 ,  C07D209/48 ,  C07D215/38 ,  C07D401/06 ,  C07D237/30 ,  C07D217/24

CPC classification number: C07D413/12 ,  C07D209/48 ,  C07D215/24 ,  C07D215/38 ,  C07D217/24 ,  C07D237/30 ,  C07D401/06 ,  C07D401/12 ,  C07D471/04

Abstract: The invention encompasses compound and pharmaceutical composition comprising the compound of the following Formula (I): or pharmaceutically acceptable salts or prodrugs thereof, that are useful for inhibiting ezrin protein in a cell or for inhibiting the growh of a cancer cell.

公开(公告)号：US12016834B2

公开(公告)日：2024-06-25

申请号：US16636226

申请日：2018-08-03

Applicant: GEORGETOWN UNIVERSITY ,  GEORGE MASON UNIVERSITY

Inventor： Maria Laura Avantaggiati ,  Mikell Paige

IPC: A61K31/18 ,  A61P35/04 ,  A61K45/06

CPC classification number: A61K31/18 ,  A61P35/04 ,  A61K45/06

Abstract: Methods of treating or preventing cancer, diabetes, and/or obesity in a subject are provided. The methods comprise administering to a subject a therapeutically effective amount of an SLC25A1 inhibitor as described herein. Also provided herein are pharmaceutical compositions comprising an SLC25A1 inhibitor and a chemotherapeutic agent. Further provided herein are methods of inhibiting SLC25A1 in a cell.

公开(公告)号：US09522908B2

公开(公告)日：2016-12-20

申请号：US14047362

申请日：2013-10-07

Applicant: Georgetown University

Inventor： Milton L. Brown ,  Mikell Paige ,  Jeffrey A. Torestsky ,  Aykut Uren ,  George Kosturko ,  Gullay Bulut

IPC: C07D215/38 ,  A61K31/535 ,  A61K31/47 ,  C07D413/12 ,  C07D209/48 ,  C07D215/24 ,  C07D217/24 ,  C07D401/12 ,  C07D471/04 ,  C07D237/30 ,  C07D401/06

CPC classification number: C07D413/12 ,  C07D209/48 ,  C07D215/24 ,  C07D215/38 ,  C07D217/24 ,  C07D237/30 ,  C07D401/06 ,  C07D401/12 ,  C07D471/04

Abstract: The invention encompasses compound and pharmaceutical composition comprising the compound of the following Formula (I): or pharmaceutically acceptable salts or prodrugs thereof, that are useful for inhibiting ezrin protein in a cell or for inhibiting the growth of a cancer cell.

Abstract translation: 本发明包括可用于抑制细胞中ezrin蛋白或抑制癌细胞生长的下式（I）化合物或其药学上可接受的盐或前药的化合物和药物组合物。

公开(公告)号：US20200246285A1

公开(公告)日：2020-08-06

申请号：US16636226

申请日：2018-08-03

Applicant: GEORGETOWN UNIVERSITY

Inventor： Maria Laura Avantaggiati ,  Mikell Paige

IPC: A61K31/18 ,  A61P35/04

Abstract: Methods of treating or preventing cancer, diabetes, and/or obesity in a subject are provided. The methods comprise administering to a subject a therapeutically effective amount of an SLC25A1 inhibitor as described herein. Also provided herein are pharmaceutical compositions comprising an SLC25A1 inhibitor and a chemotherapeutic agent. Further provided herein are methods of inhibiting SLC25A1 in a cell.

公开(公告)号：US20140135325A1

公开(公告)日：2014-05-15

申请号：US14047362

申请日：2013-10-07

Applicant: GEORGETOWN UNIVERSITY

Inventor： Milton L. Brown ,  Mikell Paige ,  Jeffrey A. Torestsky ,  Aykut Uren ,  George Kosturko ,  Gullay Bulut

IPC: C07D413/12 ,  C07D237/30 ,  C07D401/12 ,  C07D217/24 ,  C07D215/38 ,  C07D401/06 ,  C07D471/04

CPC classification number: C07D413/12 ,  C07D209/48 ,  C07D215/24 ,  C07D215/38 ,  C07D217/24 ,  C07D237/30 ,  C07D401/06 ,  C07D401/12 ,  C07D471/04

Abstract: The invention encompasses compound and pharmaceutical composition comprising the compound of the following Formula (I): or pharmaceutically acceptable salts or prodrugs thereof, that are useful for inhibiting ezrin protein in a cell or for inhibiting the growth of a cancer cell.

Abstract translation: 本发明包括可用于抑制细胞中ezrin蛋白或抑制癌细胞生长的下式（I）化合物或其药学上可接受的盐或前药的化合物和药物组合物。